Australian research shows DOAC reversal with off-label, non-specific haemostatic agents is effective – but the risk of a thromboembolic complication needs to be carefully considered in a high-risk patient group. A retrospective study comprised a medical record review of all 51 patients who were prescribed either a 3 factor-prothrombin complex concentrate (3F-PCC) or activated prothrombin ...
Call for local guidelines on DOAC reversal with non-specific haemostatic agents
By Mardi Chapman
17 Nov 2021